NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study.
NAFLD Associates with Sarcopenia Defined by Muscle Mass and Slow Walking Speed: A Cross-Sectional Analysis from the Framingham Heart Study.
复制标题
NAFLD与肌肉质量和步行速度缓慢定义的肌肉减少症：弗雷明汉心脏研究的横断面分析。
DOI：
10.3390/jcm12247523
复制
发表时间：
2023-12-06
影响因子：
3.9
通讯作者：
中科院分区：
文献类型：
--
作者：
肌肉减少症与NAFLD相关。尚不清楚这种关联是否由共同的风险因素解释。我们的研究旨在调查我们队列中肝脏脂肪和肌肉减少症之间的关系。在2008年至2011年期间通过CT测量肝脏脂肪。我们排除了重度饮酒和缺失的协变量。通过24 h尿肌酐测量亚组（n = 485）中的肌肉质量。身体功能由h力量和步行速度定义。肌肉减少症定义为低肌肉质量和/或低身体功能。我们建立了多变量调整回归模型，以评估肝脏脂肪和低肌肉质量，握力和步行速度之间的横截面关联。肝脂肪变性的患病率为30%（n = 1073; 58.1%为女性;平均年龄65.8 ± 8.6岁）。在线性回归模型中，肝脏脂肪和肌肉质量之间存在显著的正相关。在调整BMI后，这种关联并不显著。对于肝脏脂肪的每个SD，肌肉减少症的几率增加28%（OR 1.28; 95% CI 1.02，1.60），并且在多变量校正模型中考虑混杂因素后持续存在（OR 1.30，95% CI 1.02，1.67）。需要进一步的研究来确定肝脏脂肪和肌肉减少症之间是否存在因果关系，以及肌肉减少症的治疗是否可以改善肝脏脂肪。
Sarcopenia is associated with NAFLD. It is unknown if the association is explained by shared risk factors. Our study sought to investigate the association between liver fat and sarcopenia in our cohort. Liver fat was measured on CT between 2008 and 2011. We excluded heavy alcohol use and missing covariates. Muscle mass in a subset (n = 485) was measured by 24 h urinary creatinine. Physical function was defined by h strength and walking speed. Sarcopenia was defined as low muscle mass and/or low physical function. We created multivariable-adjusted regression models to evaluate cross-sectional associations between liver fat and low muscle mass, grip strength, and walking speed. The prevalence of hepatic steatosis was 30% (n = 1073; 58.1% women; mean age 65.8 ± 8.6 years). There was a significant positive association between liver fat and muscle mass in linear regression models. The association was not significant after adjusting for BMI. The odds of sarcopenia increased by 28% for each SD in liver fat (OR 1.28; 95% CI 1.02, 1.60) and persisted after accounting for confounders in multivariable-adjusted models (OR 1.30, 95% CI 1.02, 1.67). Further studies are needed to determine if there is a causal relationship between liver fat and sarcopenia and whether treatment of sarcopenia improves liver fat.
登录
查看更多内容
影响因子：
24.5
作者：
Kaser, S;Moschen, A;Tilg, H
通讯作者：
Tilg, H
影响因子：
7
作者：
Heymsfield, Steven B.;Gonzalez, M. Cristina;Zheng, Jolene
通讯作者：
Zheng, Jolene
影响因子：
25.7
作者：
Lee, Yong-ho;Jung, Kyu Sik;Cha, Bong-Soo
通讯作者：
Cha, Bong-Soo
影响因子：
13.1
作者：
Kalinkovich, Alexander;Livshits, Gregory
通讯作者：
Livshits, Gregory
DOI：
10.1067/mlc.2001.113504
发表时间：
2001-04-01
期刊：
JOURNAL OF LABORATORY AND CLINICAL MEDICINE
影响因子：
--
作者：
Morley, JE;Baumgartner, RN;Nair, KS
通讯作者：
Nair, KS